PUBLIC COMPANY
saveTessera Therapeutics Inc
updated 2mo ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Preclinical1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
Where Tessera Therapeutics Inc is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaRare Disease 2CNS / Neuroscience 1Hematology 1
News
- MindMaze trims Relief staff, Aardvark cuts workforce amid Prader-Willi troublesFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- Chutes & Ladders—Legend CEO departs without successor in placeLegend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…fiercebiotech · 15d ago
- STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATDBiotech companies are racing to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes, startup defections, arbitration, and a U.S.-China rivalry.stat · 17d ago
- Sarepta names former AbbVie R&D exec Michael Severino as next CEOAfter leaving Tessera Therapeutics earlier this month, Michael Severino will take over Sarepta Therapeutics as the biotech awaits two key regulatory decisions in Duchenne muscular dystrophy.biospace · 18d ago
- Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEOMost recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company facing emerging competition and declining sales for its prized gene therapy E…biopharma_dive · 18d ago
- STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executiveThe beleaguered Sarepta Therapeutics named Michael Severino, who previously led Tessera Therapeutics, as its new CEO.stat · 18d ago
- Chutes & Ladders—Biogen R&D vet gets in FormationAI-focused Formation Bio has found a new chief scientist with extensive experience in biotech, Big Pharma and academia. Michael Ehlers, M.D., Ph.D., is joining the 2025 Fierce 15 honoree as chief s…fiercebiotech · 22d ago
- #ASGCT26: Tessera reveals strongest data yet for in vivo sickle cell therapyBOSTON — Tessera Therapeutics has created an experimental gene editing drug for sickle cell disease that could compete with commercial cell therapies but is delivered as an infusion — no complex ce…endpoints · 3mo ago
- Fierce Biotech Layoff Tracker 2026: Aura loses 20% of staffers; aTyr shrinks by 60%As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.fiercebiotech · 7mo ago
comments(0)
5-min edit window · permanent after that